News
-
-
-
COMMUNIQUÉ DE PRESSE
(Pr)CABTREO(MC) (phosphate de clindamycine, adapalène et gel de peroxyde de benzoyle), un traitement pour l'acné vulgaire, reçoit des recommandations de remboursement de l'Agence des médicaments du Canada et de l'INESSS, au Québec
Bausch Health, Canada Inc., une filiale de Bausch Health Companies Inc., annonce des recommandations positives de remboursement de CABTREO, un nouveau traitement topique triple pour l'acné vulgaire, par l'AMC et l'INESSS -
COMMUNIQUÉ DE PRESSE
PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS
Bausch Health, Canada announces positive reimbursement recommendations for new acne treatment CABTREO, the first triple-combination topical therapy approved in Canada -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
Bausch Health's additional ACG presentation to focus on Xifaxan impact on OHE rehospitalizations and Plenvu bowel preparation efficacy at ACG 2024. Posters to share findings on treatments
